Generic Name and Formulations:
Meropenem, vaborbactam 2g/vial (containing meropenem 1g + vaborbactam 1g); pwd for IV infusion after reconstitution and dilution; sodium content 10.9mEq/vial; preservative-free.
Indications for VABOMERE:
Susceptible complicated urinary tract infections (cUTI) including pyelonephritis.
Give by IV infusion over 3hrs. ≥18yrs (eGFR ≥50mL/min/1.73m2): 4g every 8hrs. Renal impairment (eGFR 30–49mL/min/1.73m2): 2g every 8hrs; (eGFR 15–29mL/min/1.73m2): 2g every 12hrs; (eGFR <15mL/min/1.73m2): 1g every 12hrs. Give after hemodialysis session. All: treat for up to 14 days.
<18yrs: not established.
Previous hypersensitivity to penicillins, cephalosporins, other beta-lactams, or other allergens. Discontinue immediately if allergic reaction occurs. CNS disorders (eg, brain lesions, history of seizures). Bacterial meningitis. Renal impairment (thrombocytopenia possible). Reevaluate dose if focal tremors, myoclonus, or seizures occur. Discontinue if C. difficile-associated diarrhea suspected or confirmed. Pregnancy. Nursing mothers.
Carbapenem + beta-lactamase inhibitor.
Concomitant valproic acid or divalproex sodium: not recommended; if use necessary, consider supplemental anticonvulsant. Potentiated by probenecid: not recommended.
Headache, phlebitis/infusion site reactions, diarrhea; serious hypersensitivity reactions, C. difficile-associated diarrhea, possible neuromotor impairment (eg, seizures, delirium, paresthesias), superinfection.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds